Merit Medical Systems, Inc. (NASDAQ: MMSI) launched its Resilience Through‑the‑Scope (TTS) Esophageal Stent, a device engineered to treat esophageal fistulas and strictures caused by malignant tumors. The stent features proprietary anti‑migration flanges and a single‑handed deployment system that simplifies placement for endoscopists.
The Resilience stent is available in three sizes—14 mm × 50 mm, 17 mm × 50 mm, and 20 mm × 50 mm—making it the only TTS esophageal stent on the market with this range of dimensions. The anti‑migration design is intended to reduce the most common clinical limitation of existing products, while the single‑handed delivery system improves procedural efficiency.
The global fully‑covered esophageal stent market was valued at approximately USD 320 million in 2025 and is projected to grow as the incidence of esophageal cancer and benign strictures rises. Boston Scientific and Cook Medical dominate the market, but Merit’s unique sizing and migration‑resistance features position the Resilience stent as a differentiated option for clinicians seeking reliable long‑term outcomes.
Merit’s endoscopy segment currently accounts for about 5 % of total company revenue and grew 15 % in Q4 2025. The new stent adds to this high‑growth segment, helping the company offset headwinds such as tariff impacts, weaker OEM demand, and the divestiture of the DualCap product line. The launch aligns with the company’s 2026 guidance of 6 %–8 % revenue growth and supports its broader strategy to expand its endoscopy portfolio.
"The Resilience TTS Esophageal Stent fulfills an unmet need with its unique sizes, design, easy‑to‑use delivery system, and anti‑migration properties," said Stuart K. Amateau, MD, PhD, Professor and Chief Division of Gastroenterology, Hepatology, and Nutrition at the University of Minnesota Medical Center. "The Resilience stent addresses several well‑known clinical disadvantages of currently available TTS esophageal stents. This launch signifies another step forward in the rapidly growing TTS stent‑technology market," added Merit President and CEO Martha G. Aronson.
The product launch positions Merit to capture a growing patient population with malignant esophageal disease, the sixth most common cause of cancer deaths worldwide. By expanding its endoscopy offerings and introducing a device that addresses key clinical challenges, Merit strengthens its competitive stance and supports its long‑term growth objectives.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.